Arvinas (ARVN) Competitors $7.70 -0.12 (-1.47%) As of 03:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARVN vs. CNTA, DNLI, IBRX, AGIO, IDYA, OCUL, HRMY, IRON, CGON, and RXRXShould you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), ImmunityBio (IBRX), Agios Pharmaceuticals (AGIO), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), Harmony Biosciences (HRMY), Disc Medicine (IRON), CG Oncology (CGON), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. Arvinas vs. Its Competitors Centessa Pharmaceuticals Denali Therapeutics ImmunityBio Agios Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Harmony Biosciences Disc Medicine CG Oncology Recursion Pharmaceuticals Centessa Pharmaceuticals (NASDAQ:CNTA) and Arvinas (NASDAQ:ARVN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation. Do analysts rate CNTA or ARVN? Centessa Pharmaceuticals currently has a consensus price target of $32.70, indicating a potential upside of 50.28%. Arvinas has a consensus price target of $19.76, indicating a potential upside of 159.19%. Given Arvinas' higher probable upside, analysts plainly believe Arvinas is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08Arvinas 0 Sell rating(s) 10 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.55 Which has preferable earnings & valuation, CNTA or ARVN? Arvinas has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M425.38-$235.76M-$1.79-12.16Arvinas$263.40M2.13-$198.90M-$1.01-7.55 Does the media prefer CNTA or ARVN? In the previous week, Centessa Pharmaceuticals had 10 more articles in the media than Arvinas. MarketBeat recorded 16 mentions for Centessa Pharmaceuticals and 6 mentions for Arvinas. Arvinas' average media sentiment score of 1.59 beat Centessa Pharmaceuticals' score of 0.63 indicating that Arvinas is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arvinas 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders and institutionals believe in CNTA or ARVN? 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 7.1% of Centessa Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, CNTA or ARVN? Centessa Pharmaceuticals has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 2.38, meaning that its stock price is 138% more volatile than the S&P 500. Is CNTA or ARVN more profitable? Centessa Pharmaceuticals has a net margin of 0.00% compared to Arvinas' net margin of -19.47%. Arvinas' return on equity of -12.01% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -40.39% -29.87% Arvinas -19.47%-12.01%-6.97% SummaryArvinas beats Centessa Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARVN vs. The Competition Export to ExcelMetricArvinasMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$558.95M$3.15B$5.81B$10.17BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-7.5421.3774.6226.02Price / Sales2.13294.32466.0690.52Price / CashN/A45.3337.0859.91Price / Book0.939.6212.166.30Net Income-$198.90M-$53.29M$3.29B$270.86M7 Day Performance-2.62%0.35%1.07%3.41%1 Month Performance12.30%8.99%7.38%6.56%1 Year Performance-68.89%12.97%63.13%28.27% Arvinas Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARVNArvinas3.0098 of 5 stars$7.70-1.5%$19.76+156.8%-68.6%$563.79M$263.40M-7.60420Positive NewsCNTACentessa Pharmaceuticals3.2051 of 5 stars$16.79+1.4%$31.50+87.6%+64.9%$2.25B$6.85M-9.38200Insider TradeDNLIDenali Therapeutics4.3906 of 5 stars$15.27-2.4%$33.62+120.1%-45.3%$2.23B$330.53M-5.45430Positive NewsIBRXImmunityBio2.516 of 5 stars$2.34+0.4%$10.75+359.4%-28.5%$2.21B$14.74M-4.87590Analyst ForecastAGIOAgios Pharmaceuticals4.3418 of 5 stars$37.71-1.2%$56.33+49.4%-17.6%$2.19B$36.50M3.43390Insider TradeIDYAIDEAYA Biosciences4.002 of 5 stars$24.55-1.5%$47.10+91.9%-31.1%$2.15B$7M-6.4880Analyst ForecastAnalyst RevisionOCULOcular Therapeutix3.9381 of 5 stars$12.21-2.5%$17.20+40.9%+51.3%$2.12B$63.72M-9.54230HRMYHarmony Biosciences4.62 of 5 stars$36.89-2.8%$51.00+38.2%-10.4%$2.12B$772.53M11.90200Positive NewsIRONDisc Medicine3.2574 of 5 stars$59.650.0%$98.30+64.8%+24.3%$2.07BN/A-13.3430Positive NewsCGONCG Oncology2.1994 of 5 stars$26.82+0.4%$54.30+102.5%-9.2%$2.04B$551K-15.1561RXRXRecursion Pharmaceuticals2.1622 of 5 stars$4.70-3.3%$7.00+48.9%-24.8%$2.04B$58.84M-2.64400News CoverageAnalyst ForecastOptions VolumeGap Up Related Companies and Tools Related Companies CNTA Competitors DNLI Competitors IBRX Competitors AGIO Competitors IDYA Competitors OCUL Competitors HRMY Competitors IRON Competitors CGON Competitors RXRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARVN) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
